Loading data for ENLV — first visit, this takes a few seconds.
Enlivex Ltd. (ENLV) Stock Price, Analysis & Data
Intrinsic Value
Analyst Forecast
Stock Forecasts →Latest Earnings
| Reported | Vs estimate | YoY Change | |
|---|---|---|---|
| Revenue | — | n/a | n/a |
| EPS | — | n/a | n/a |
Metrics
- Bid
- 0.84
- Market Cap
- 16.8M
- Revenue (ttm)
- n/a
- Net Income (ttm)
- 1.24B
- 1.42
- 382.2
- 0
- -1.23
- P/B (ttm)
- 0.01
- P/S (ttm)
- n/a
- Earnings Date
- n/a
- Ask
- 1.33
- Volume
- 252,141
- Avg. Volume (20D)
- 226,959
- Open
- 1.15
- Previous Close
- 1.16
- Day's Range
- 1.02 - 1.15
- 52-Week Range
- 1.02 - 27.15
- Analyst
- n/a
- Price Target
- n/a
- Dividends
- n/a
- Ex-Dividend Date
- n/a
About Enlivex Ltd.
View profile →Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026. The company was founded in 2005 and is headquartered in Ness Ziona, Israel.
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026. The company was founded in 2005 and is headquartered in Ness Ziona, Israel.
Industry Biotechnology
Sector Healthcare
IPO Date Jul 31, 2014
Employees 34
Stock Exchange NasdaqCM
Ticker Symbol ENLV
Website https://www.enlivex.com